With the imminent completion of the human genome sequence, scientists are now faced with the daunting task of discovering the biological function of each gene and the consequence of the small variations, or polymorphisms, that make one individual different from another. As these sequence variations are identified, they will undoubtedly be linked to human diseases, including diseases caused by exposure to environmental agents. Transgenic mouse models are very powerful tools for studying the function of genes and gene variants in the context of a whole organism. The proposed mouse models in this application will focus on genes and gene variants involved in cell cycle regulation and DNA damage checkpoint control. Standard transgenic and knockout technologies, as well as new conditional and inducible technologies, will be used to develop these models. These mouse models will be characterized at the histopathological and molecular levels and their response to carcinogenic agents, both chemical and UV radiation, will be analyzed. New functional genomic technologies will be used to perform an in-depth analysis of the changes in gene expression that occur in these mouse models as a result of the specific genetic alterations and in response to carcinogen exposure. The studies will initially be focused on the skin as a model organ system. However, because of the nature of the transgenes and targeting constructs to be used in generating these models, there is also the potential to study other epithelial tissues, including the prostate, mammary gland, thymus, bladder, gall bladder, and upper aerodigestive tract. This group of investigators has expertise in transgenic mouse development, molecular biology (particularly as it relates to the cell cycle), pathology, mouse genetics, carcinogenesis, biostatistics, and functional genomics. The senior investigators have experience in the mouse skin system and have previously worked together to develop and characterize transgenic mouse models. The scientific goals of the proposed studies are to determine the following: 1) the biological properties of a variant of cyclin Dl, 2) the mechanism by which E2Fl suppresses tumorigenesis, 3) the normal function of BRCA1 and PTEN in regulating epithelial tissue homeostasis, and 4) the role of a human p2l polymorphic variant in cancer susceptibility. In addition, the transgenic model approaches and functional genomic tools that will be developed will hopefully be applicable for the development and characterization of additional mouse models based on new discoveries of genetic variations in humans.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01ES011047-05S1
Application #
7217662
Study Section
Special Emphasis Panel (ZES1)
Program Officer
Tyson, Frederick L
Project Start
2001-04-01
Project End
2007-03-31
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
5
Fiscal Year
2006
Total Cost
$569,259
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Organized Research Units
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Post, Sean M; Quintás-Cardama, Alfonso; Pant, Vinod et al. (2010) A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 18:220-30
Zhu, Feng; Dolle, Martijn E T; Berton, Thomas R et al. (2010) Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res 70:5851-9
Kataoka, Ken; Kim, Dae Joon; Carbajal, Steve et al. (2008) Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis. Carcinogenesis 29:1108-14
Chan, K S; Sano, S; Kataoka, K et al. (2008) Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. Oncogene 27:1087-94
Wang, Aijin; Arantes, Stacey; Conti, Claudio et al. (2007) Epidermal hyperplasia and oral carcinoma in mice overexpressing the transcription factor ATF3 in basal epithelial cells. Mol Carcinog 46:476-87
Zhang, Zhengdong; Wang, Li-E; Sturgis, Erich M et al. (2006) Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12:5596-602
Kim, Jeesun; Daniel, Jeremy; Espejo, Alexsandra et al. (2006) Tudor, MBT and chromo domains gauge the degree of lysine methylation. EMBO Rep 7:397-403
Li, Guojun; Liu, Zhensheng; Sturgis, Erich M et al. (2005) Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 26:1596-602
Zhang, Zhengdong; Shi, Qiuling; Sturgis, Erich M et al. (2005) Polymorphisms and haplotypes of serine hydroxymethyltransferase and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Pharmacogenet Genomics 15:557-64
Rundhaug, Joyce E; Hawkins, Kathleen A; Pavone, Amy et al. (2005) SAGE profiling of UV-induced mouse skin squamous cell carcinomas, comparison with acute UV irradiation effects. Mol Carcinog 42:40-52

Showing the most recent 10 out of 21 publications